Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Financing Activities: 2010-2024

Historic Cash from Financing Activities for Kura Oncology (KURA) over the last 14 years, with Dec 2024 value amounting to $154.4 million.

  • Kura Oncology's Cash from Financing Activities fell 83.06% to $515,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $154.4 million for FY2024, which is 62.92% up from last year.
  • According to the latest figures from FY2024, Kura Oncology's Cash from Financing Activities is $154.4 million, which was up 62.92% from $94.8 million recorded in FY2023.
  • In the past 5 years, Kura Oncology's Cash from Financing Activities registered a high of $469.3 million during FY2020, and its lowest value of -$3.4 million during FY2021.
  • In the last 3 years, Kura Oncology's Cash from Financing Activities had a median value of $94.8 million in 2023 and averaged $95.9 million.
  • As far as peak fluctuations go, Kura Oncology's Cash from Financing Activities slumped by 100.73% in 2021, and later surged by 1,222.71% in 2022.
  • Over the past 5 years, Kura Oncology's Cash from Financing Activities (Yearly) stood at $469.3 million in 2020, then tumbled by 100.73% to -$3.4 million in 2021, then spiked by 1,222.71% to $38.6 million in 2022, then surged by 145.77% to $94.8 million in 2023, then surged by 62.92% to $154.4 million in 2024.